Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [3] Core Insights - The strategic position of the biopharmaceutical industry has been elevated, with innovative drugs, medical devices, and elderly care services expected to face structural opportunities in the medium to long term [2][36] - The 2026 government work report has classified the biopharmaceutical industry as a pillar industry alongside integrated circuits and aerospace, emphasizing its importance in the national economy [33][36] - There is a shift towards "full-chain support" for innovative drug development, with policies moving from macro-level support to practical payment systems, indicating a new era of diversified payment methods for innovative drugs [37][38] Summary by Sections Market Review - The biopharmaceutical index fell by 2.78% this week, underperforming the CSI 300 index by 1.71 percentage points, ranking 17th in industry performance [14] - Year-to-date, the biopharmaceutical index has increased by 0.1%, also underperforming the CSI 300 index by 0.56 percentage points, ranking 24th [14] Individual Stock Performance - In the A-share market, among 480 biopharmaceutical stocks, 75 stocks rose, accounting for 15.63%. The top five gainers were: - Yahui Pharmaceutical (+38.11%) - Zhejiang Medicine (+12.83%) - Zhongyuan Xiehe (+12.69%) - Duorui Pharmaceutical (+12.55%) - Jiuan Medical (+10.48%) [27][28] - In the Hong Kong market, 116 biopharmaceutical stocks saw 23 rise, making up 19.83%. The top ten gainers included: - Yaojie Ankang-B (+33.53%) - Deqi Pharmaceutical-B (+19.57%) - Baize Medical (+12.87%) [30][31] Industry News and Policies - The biopharmaceutical industry has been explicitly included in the national "emerging pillar industries" category, with policies aimed at enhancing multi-level medical insurance systems and promoting the development of innovative drugs and medical devices [33] - The government is encouraging commercial health insurance to cover more reasonable medical expenses outside the basic medical insurance directory, which is expected to boost investment in innovative drug development [38] Weekly Insights - The report suggests focusing on the long-term development of the biopharmaceutical industry, particularly on innovative drug and device companies that are pioneering in their fields, as well as the related industries in the silver economy [39]

Group 1: Berteli / Automotive Parts - The company plans to acquire 50.9727% of Yubei Steering, enhancing its steering business capabilities. The acquisition involves purchasing shares from multiple stakeholders, with a valuation not exceeding 2.2 billion yuan [3] - Yubei Steering's main business includes the production and sales of automotive steering systems and components, with projected revenues of 3.03 billion yuan and 3.18 billion yuan for 2024 and 2025, respectively [3] - The company has strong development capabilities in mechanical and electronic brake products, aiming to innovate continuously in vehicle brake systems and provide comprehensive solutions [4] Group 2: Geely Automobile - Geely's total sales in February 2026 reached 206,000 units, showing a slight year-on-year increase of 0.6%, while the cumulative sales for January-February were 476,000 units, up 1.0% year-on-year [6][7] - The company is focusing on high-end product launches, with several new models set to debut in the first half of 2026, including the flagship SUV 8X and the hybrid SUV M7 [7][8] - Geely's export performance is strong, with February exports reaching 61,000 units, a year-on-year increase of 138.3%, and cumulative exports for January-February at 121,000 units, up 129.4% [8] Group 3: Great Wall Motors - Great Wall Motors sold 73,000 vehicles in February 2026, with a cumulative sales increase of 2.6% year-on-year for January-February [10][11] - The company aims to achieve a total sales target of 1.8 million vehicles for 2026, with 600,000 units expected to come from overseas markets [11][12] - The upcoming V9X model, a luxury six-seat SUV, is set to launch in the second quarter of 2026, featuring advanced technology and performance specifications [12] Group 4: Leap Motor - Leap Motor delivered 28,000 vehicles in February 2026, marking an 11.0% year-on-year increase, with a cumulative delivery of 60,000 units for January-February, up 19.2% [14][15] - The company plans to launch several new models in 2026, including the A10, which emphasizes intelligent features and long-range capabilities [15] - Leap Motor is initiating a new retail strategy to enhance customer experience and diversify sales channels [15] Group 5: Swine Breeding Industry - The swine breeding industry is facing intensified losses, with a potential restart of capacity reduction measures. The national breeding sow inventory decreased by 2.9% year-on-year as of December 2025 [17][18] - The industry is seeing increased concentration, with the top 20 swine breeding companies accounting for 36% of the market share, up 5 percentage points year-on-year [17] - The report suggests a left-side layout for the swine breeding sector, recommending leading companies such as Muyuan Foods and Wens Foodstuffs [18] Group 6: BeiGene / Chemical Pharmaceuticals - BeiGene reported a total revenue of $5.34 billion in 2025, a 40% year-on-year increase, with product revenue also growing by 40% [25][26] - The company expects to achieve revenue guidance of $6.2 to $6.4 billion for 2026, with significant contributions from its key products [25] - The rapid growth of its drug Zebrutinib, particularly in the U.S. market, is a key driver of revenue, with a global sales figure of $3.9 billion in 2025 [26][27]

Investment Rating - The overall industry rating is neutral, indicating that the expected return over the next six months is between -5% and 5% relative to the CSI 300 index [8]. Core Insights - The pharmaceutical sector experienced a decline of 2.67% on March 3, 2025, underperforming the CSI 300 index by 1.13 percentage points, ranking 14th among 31 sub-industries in the Shenwan classification [4]. - Notable performances within sub-industries included offline pharmacies (-0.62%), blood products (-1.37%), and in vitro diagnostics (-1.50%), while hospitals (-4.32%), medical R&D outsourcing (-3.53%), and other biological products (-3.39%) lagged behind [4]. - Key individual stock performances included Kanghui Co., Ltd. (+10.01%), Lianhuan Pharmaceutical (+3.89%), and Jiuan Medical (+3.42%) on the gainers' list, while Tianzhihang (-11.45%), Saike Xide (-11.06%), and Wanze Co., Ltd. (-10.01%) were among the biggest losers [4]. Sub-industry Ratings - Chemical pharmaceuticals: No rating - Traditional Chinese medicine production: No rating - Biopharmaceuticals II: Neutral - Other pharmaceuticals: Neutral [3]. Industry News - Eli Lilly's Lebrikizumab, an anti-IL-13 monoclonal antibody, has received acceptance for market application in China, having previously been approved by the FDA in the U.S. for moderate to severe atopic dermatitis [5]. - Yihong Pharmaceutical's APL-1702 has been approved for the treatment of confirmed CIN2 patients aged 18 and above [5]. - Baiyao's Usymro has received approval from the UK Medicines and Healthcare products Regulatory Agency, enhancing the company's international presence [5]. - Yiling Pharmaceutical's chemical raw material drug, Pomalidomide, has been approved for market application [6]. - Haichuang Pharmaceutical's HP515, a selective THR-β agonist for treating metabolic-associated fatty liver disease, has completed participant enrollment in its Phase IIa clinical trial [6].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [3] Core Insights - The pharmaceutical excipients industry is entering a mature phase, with a focus on leading companies in pharmaceutical excipients [9] - The report highlights the increasing specialization and scale of the pharmaceutical excipients industry in China, driven by improved regulatory and standard systems [9][36] - The demand for plant-based capsules is expected to grow significantly, particularly in the Chinese market, with projections indicating a market size of approximately 423.7 billion yuan by 2027 [39] Summary by Sections Market Review - The pharmaceutical biotechnology index rose by 0.5% this week, underperforming the CSI 300 index by 0.58 percentage points, ranking 25th in industry performance [14] - Year-to-date, the pharmaceutical biotechnology index has increased by 2.96%, outperforming the CSI 300 index by 1.21 percentage points, ranking 24th [14] Sub-industry Performance - Among sub-industries, biological products increased by 2.56%, medical devices by 2.16%, and pharmaceutical commerce by 1.13%, while chemical pharmaceuticals and medical services decreased by 0.64% and 0.99%, respectively [21] - The medical services sub-sector has shown the highest growth at 9.4% year-to-date, while chemical pharmaceuticals have the lowest growth with a decline of 1.65% [21] Key Company Announcements - Aibo Medical plans to acquire 68.31% of the shares of Demei Medical for approximately 6.83 billion yuan, with performance commitments set for the next three years [33] - GSK's new oral targeted drug, Linerixibat, has been accepted for market registration in China, aimed at treating primary biliary cholangitis [33] - Hansoh Pharmaceutical's new lung cancer drug, Amivantamab, has been approved for sale in the EU [34] Industry Trends - The report emphasizes the importance of pharmaceutical excipients in drug formulation and their impact on drug efficacy and manufacturing processes [36] - The new version of the Chinese Pharmacopoeia, effective from October 1, 2025, will enhance the quality of domestic pharmaceutical excipients and improve their competitiveness in international markets [36] - The market for plant-based capsules is expected to expand significantly, driven by the growth of the health supplement industry and the demand for high-quality pharmaceutical excipients [39]

Financial Performance - The company achieved total operating revenue of 964,930,489.25 yuan in 2025, representing a year-on-year increase of 7.63% [1][2] - The net profit attributable to the parent company was 258,668,187.82 yuan, reflecting a year-on-year growth of 17.94% [1][2] - As of the end of the reporting period, total assets amounted to 2,709,928,593.09 yuan, an increase of 7.22% compared to the beginning of the period [1] - The equity attributable to the parent company reached 2,427,107,981.56 yuan, up by 7.94% from the start of the period [1] Business Development - The company has strengthened team building and market development, leading to growth in both total operating revenue and net profit [2] - Sales revenue from the main product, Nigulazole tablets, has maintained a rapid growth trend [2] - The company is actively advancing the research and development of new drugs, including the antidepressant JJH201501 and the anti-tumor drug JJH201601 [2] - The Phase III clinical trial for the antidepressant JJH201501 has been successfully completed, while the Phase IIa clinical trial for the anti-tumor drug JJH201601 is progressing smoothly [2] Incentive Mechanism - To establish and improve the company's long-term incentive mechanism, a restricted stock incentive plan for 2025 has been formulated and implemented [2] - The share-based payment expenses for the reporting period amounted to 23,506,400 yuan (unaudited, final data to be confirmed in the audited annual report) [2]

Core Viewpoint - Hunan Warner Pharmaceutical Co., Ltd.'s subsidiary has successfully obtained GMP certification from Brazil's National Health Surveillance Agency (ANVISA) for the active pharmaceutical ingredient fosfomycin trometamol, enabling market entry into Brazil and enhancing international competitiveness [1][2]. Group 1: Certification Details - The GMP certification was issued for Hunan Warner Pharmaceutical Chiral Drugs Co., Ltd. for the production of fosfomycin trometamol [1]. - The certification number is 1435341/23-6, and it is valid until January 19, 2028 [1]. - The production facility is located at 139 Tongguan Avenue, Tongguan Circular Economy Industrial Base, Wangcheng District, Changsha, Hunan Province [1]. Group 2: Product Information - Fosfomycin trometamol is used as an active ingredient in formulations for treating acute uncomplicated urinary tract infections caused by sensitive strains of Escherichia coli, Enterococcus faecalis, Klebsiella pneumoniae, Citrobacter species, Enterobacter species, and Proteus mirabilis [1]. Group 3: Market Impact - The successful GMP certification lays a solid foundation for expanding into the Brazilian market and other international markets, thereby enhancing the company's international competitiveness [2].

Financial Performance Summary - In 2025, the company achieved operating revenue of 525.57 million RMB, representing a year-on-year increase of 23.09% [2] - The net profit attributable to the parent company was 114.02 million RMB, showing a significant year-on-year growth of 122.01% [2] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 116.59 million RMB, with a year-on-year increase of 102.99% [2] - Total assets at the end of the reporting period reached 1,955.93 million RMB, up 11.35% year-on-year [2] - The equity attributable to the parent company was 1,492.15 million RMB, reflecting a year-on-year growth of 7.11% [2] Business Operations and Key Factors - The company's core business segment, DEL, maintained steady growth, contributing to overall profit enhancement due to high gross margins [3] - The UK subsidiary further solidified the development of the FBDD/SBDD platform, with milestone revenues achieved from client projects [3] - The OBT segment showed significant revenue growth through the commercialization of small nucleic acid projects, aided by the efficient operation of an automated high-throughput chemical synthesis platform [3] - The company reported a significant increase in operating profit of 125.67 million RMB, a year-on-year growth of 99.58% [5] - The total profit reached 125.91 million RMB, marking a year-on-year increase of 100.62% [5] Non-Operating Gains and Losses - The company experienced a decrease in fair value losses on financial liabilities, which positively impacted overall financial performance [4]

Core Viewpoint - The company reported significant growth in its financial performance for the year 2025, driven by increased demand in the peptide drug market, particularly in the areas of glucose-lowering and weight-loss medications [2][4]. Financial Data and Indicators - The company achieved an operating income of 741.34 million yuan, representing a year-on-year increase of 62.55% [2]. - The net profit attributable to the parent company was 165.82 million yuan, up 231.49% from the previous year [2]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was 172.65 million yuan, reflecting a growth of 278.52% [2]. Financial Condition - As of the end of 2025, the total assets of the company amounted to 1.937 billion yuan, an increase of 17.55% compared to the beginning of the reporting period [3]. - The equity attributable to the parent company was 1.065 billion yuan, which is a growth of 16.02% from the start of the period [3]. Factors Influencing Operating Performance - The company's focus on the synergistic development of its core business in peptide drug CDMO, raw materials, and formulations has led to a significant increase in sales of GLP-1 raw materials, contributing to the substantial improvement in operating performance [4]. - The increase in total operating income, operating profit, total profit, and net profit attributable to the parent company, as well as the basic earnings per share, was primarily due to the company's proactive expansion of its raw material market both domestically and internationally [5]. Changes Exceeding 30% - The company experienced significant changes exceeding 30% in various financial metrics, attributed to the successful implementation of new production capacity and increased sales of semaglutide and teriparatide raw materials [5]. - The company's share capital increased by more than 30% due to a capital reserve conversion, resulting in an increase in the number of shares from 112,418,556 to 157,385,978 [5].

Core Viewpoint - The company reported a positive performance for the fiscal year 2025, with significant increases in both revenue and net profit, indicating strong operational health and growth potential in its product lines [1] Financial Performance - The company achieved total operating revenue of 965 million yuan, representing a year-on-year increase of 7.63% [1] - The net profit attributable to the parent company's shareholders was 259 million yuan, reflecting a year-on-year increase of 17.94% [1] Operational Highlights - The company has strengthened team building and market development, contributing to the growth in both revenue and net profit [1] - Sales revenue from the main product, Niquilol tablets, has maintained a rapid growth trend [1] Research and Development - The company is actively advancing the development of new drugs, including the antidepressant JJH201501 and the anti-tumor drug JJH201601 [1] - The Phase III clinical trial for the antidepressant JJH201501 has been successfully completed, while the Phase IIa clinical trial for the anti-tumor drug JJH201601 is progressing smoothly [1] Incentive Mechanism - To further establish and improve the company's long-term incentive mechanism, a restricted stock incentive plan for 2025 has been formulated and implemented [1] - The share-based payment expenses for the reporting period amounted to 23.5064 million yuan (unaudited, with final figures subject to the audited annual report) [1]

Core Insights - The company, Haizheng Shengcai, reported its 2025 annual performance, indicating a total operating revenue of 851.5873 million yuan, which represents a year-on-year growth of 0.76% [2] - The net profit attributable to the parent company's shareholders was 9.2133 million yuan, showing a significant decline of 74.05% compared to the previous year [2] Financial Performance - Total operating revenue for 2025 reached 851.5873 million yuan, reflecting a slight increase of 0.76% year-on-year [2] - The net profit attributable to the parent company was recorded at 9.2133 million yuan, marking a substantial decrease of 74.05% from the prior year [2]